TL;DR

Autologous cell therapies (made from a patient's own cells, like CAR-T) and allogeneic therapies (made from a donor, off-the-shelf) carry different insurance exposures on the manufacturing side. The autologous model is the more demanding: a patient-specific batch cannot be remade, so a manufacturing loss or a chain-of-identity error means a patient may go untreated - a property, business-interruption, and liability event at once. Allogeneic manufacturing is closer to a conventional biologic, where a lost lot is generally replaceable. Both still share the cell-and-gene-therapy clinical trial and long-tail structure; the difference is concentrated in manufacturing property, cargo, and the batch-loss profile.

Cell therapy manufacturing · Comparison

Autologous vs allogeneic cell therapy insurance.

Autologous and allogeneic cell therapies buy the same categories of coverage, but the manufacturing model changes the exposure. The autologous model - patient-specific batches that cannot be remade - carries a distinctive batch-loss and chain-of-identity profile, while allogeneic manufacturing looks more like a conventional biologic. Both sit inside the broader cell & gene therapy program with its highest clinical trial limits and long-term-follow-up tail.

Side by side

How the two models compare.

Dimension

Autologous (patient-specific)

Allogeneic (off-the-shelf)

What it is

Made from an individual patient's own cells (for example CAR-T). Each batch is patient-specific.

Made from a donor and manufactured off-the-shelf for many patients. Closer to a conventional biologic in production model.

Batch-loss exposure

Severe. A lost, contaminated, or mis-identified batch cannot simply be remade, and the patient may be unable to be treated - a property, business-interruption, and liability event at once.

Meaningful but lower. A lost batch is a property and business-interruption event, but the product can generally be re-manufactured for the patient population.

Chain of identity

Central. The product must be tracked to the correct individual patient throughout; a chain-of-identity failure is both a regulatory and a liability exposure.

Less acute at the individual level, though donor eligibility, traceability, and lot integrity remain regulated exposures.

Business interruption

A manufacturing disruption directly affects specific patients waiting for treatment, which raises both the BI and the reputational/liability stakes.

A disruption affects supply to a population and is handled more like a conventional biologic supply interruption.

Property, cargo, cryogenic

Cryogenic storage and cold-chain transport of irreplaceable patient-specific product; a freezer failure or temperature excursion can destroy a one-of-one product.

Cryogenic exposure exists, but a destroyed lot is generally replaceable from the manufacturing process.

Insurance implication

Property with validation/reprocessing, equipment breakdown, cargo/cold-chain, and products/professional coverage tuned to the patient-specific, non-repeatable reality.

A manufacturing program closer to a standard biologic CDMO, with cryogenic and cold-chain add-ons, though the clinical trial and long-tail structure of gene-modified products still applies.

The bottom line

Where the exposure actually differs.

Autologous manufacturing is the more demanding insurance problem. Because the product is made from one patient's cells and cannot be re-manufactured, a lost or mis-identified batch is not just a property loss - it can mean a patient goes untreated, which raises the liability and reputational stakes and puts chain-of-identity and chain-of-custody failures squarely in scope. The program needs property with validation and reprocessing, cryogenic equipment-breakdown, cold-chain cargo, and products and professional coverage tuned to that non-repeatable reality.

Allogeneic manufacturing looks more like a conventional biologic CDMO. A destroyed lot is generally replaceable from the process, so the batch-loss and business-interruption exposure, while real, is handled more conventionally, with cryogenic and cold-chain add-ons.

What both share is the cell-and-gene-therapy clinical trial liability structure - the highest limits and the long claims tail from FDA long-term follow-up. So the manufacturing coverage is where autologous and allogeneic diverge, while the trial-liability and long-tail structure is common to both.

Frequently asked

Common questions about cell therapy manufacturing insurance

Does autologous or allogeneic cell therapy need different insurance?

They buy the same categories of coverage, but the manufacturing exposure differs. Autologous therapies (made from a patient's own cells, like CAR-T) carry a distinctive batch-loss and chain-of-identity profile because a patient-specific batch cannot be remade - a manufacturing loss can mean a patient goes untreated. Allogeneic therapies (made from a donor, off-the-shelf) look more like a conventional biologic, where a lost lot is generally replaceable. Both still share the cell-and-gene-therapy clinical trial liability structure and the long-term-follow-up tail.

Why is autologous cell therapy manufacturing a bigger insurance exposure?

Because the product is made from one patient's cells and cannot be re-manufactured, a lost, contaminated, or mis-identified batch is not just a property loss - the patient may be unable to be treated. That makes a manufacturing loss simultaneously a property, business-interruption, and liability event, and it puts chain-of-identity and chain-of-custody failures squarely in scope. The program needs property with validation and reprocessing, cryogenic equipment breakdown, cold-chain cargo, and products and professional coverage tuned to that non-repeatable reality.

What do autologous and allogeneic cell therapies have in common for insurance?

Both share the broader cell-and-gene-therapy program structure: the highest clinical trial liability limits (gene-modified and cell products commonly $10M-$25M or more) and the long claims tail driven by FDA long-term follow-up of up to 15 years, which makes claims-made continuity, preserved retroactive dates, and a long tail load-bearing. The manufacturing coverage is where the two diverge; the clinical trial and long-tail structure is common to both.

Cell & gene therapy insurance →CGT manufacturing insurance →CAR-T insurance →All comparisons →

Cell & gene therapy coverage review

Autologous or allogeneic - let's scope the manufacturing exposure correctly.

Send your manufacturing model and program summary. A specialist returns a coverage review and a manufacturing-aware structure within one business day.